Tomer Bronshtein

Vice President, Business Development • Bonus Biogroup

Dr. Tomer Bronshtein, VP of Business Development at Bonus Biogroup, boasts over 15 years in R&D, with an intimate understanding of autologous cell therapies and tissue engineering. His knack for amplifying company value through Next Generation Therapies bridges patients, healthcare providers, and strategic partners, further solidified by his adeptness in stakeholder engagement. Previously, Dr. Bronshtein headed Bonus Biogroup’s Research Department and demonstrated leadership at Technion’s Laboratory for Cancer Drug Delivery & Cell-Based Technologies, overseeing Tech. Transfer and pioneering a cell-derived drug delivery platform. A post-doc alumnus from Nanyang Technological University, he advanced autologous cell-based cardiac restoration therapies. With many scientific papers, patents, and articles, Dr. Bronshtein’s passion lies in disseminating knowledge. Frequently invited to international conferences, he envisions leveraging science for societal well-being, aspiring for innovations that revolutionize healthcare and impact lives globally.

Also speaking

Vesna Stamenkovic

Global Vaccine Strategy Lead • Marken

Vera Araujo

Senior Director, Business Development • Andelyn Biosciences

Ohad Karnieli

Founder & Chief Executive Officer • Adva Biotechnology

Event Info


Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.